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fused together using bone (autograft) from patient’s hip, which
requires additional surgery and leads to increased co-morbidity,
blood loss, infection rate, and pelvic instability. We assessed the
cost-effectiveness of rhBMP-2 compared with autograft in spine
fusion surgery over two years from both a health care payer’s and
societal perspectives in The Netherlands. METHODS: An eco-
nomic model was developed to evaluate differences in results
between spine-fusion surgery with rhBMP-2 and fusion with
bone autograft. The cost and health-related quality-of-life asso-
ciated with both treatment options were estimated for two years
after surgery. Data were obtained from a previously published
analysis of pooled data, in which patients in the rhBMP-2 arm
showed signiﬁcant clinical improvements after surgery compared
to standard therapy. Costs were obtained according to the Dutch
costing manual, and are reported in 2007 values. RESULTS: In
The Netherlands, from the health care payer’s perspective, using
rhBMP-2 lead to extra cost of €1,520 per case, and incremental
cost-effectiveness ratio (ICER) of €27,260/QALY. Signiﬁcant
reduction in secondary interventions, and better fusion rates
associated with rhBMP-2 treatment resulted in faster return to
work and reduced productivity loss. CONCLUSIONS: The stan-
dard use of rhBMP-2 in ALIF surgery is a cost-effective treatment
option in The Netherlands from the payer’s perspective, and a
cost-saving option from the societal perspective.
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OBJECTIVES: Assess cost-effectiveness of 35 days rivaroxaban,
an oral direct Factor Xa inhibitor, versus subcutaneous enox-
aparin regimens for prevention of venous thromboembolism
(VTE) following total hip replacement (THR). METHODS:
Rivaroxaban regimens were compared with enoxaparin regimens
following THR in two large randomized controlled trials. In
RECORD1, patients received 35 days prophylaxis with rivaroxa-
ban or enoxaparin. In RECORD2, patients received 35 days
rivaroxaban or 12 days enoxaparin. In RECORD1, rivaroxaban
reduced total VTE (composite: any DVT, non-fatal PE, all-cause
mortality) by 70% versus enoxaparin after 35 days prophylaxis,
although the reduction in symptomatic VTE was not statistically
signiﬁcant. In RECORD2, 35 days rivaroxaban reduced total
VTE by 79% and symptomatic VTE by 80% versus 12 days
enoxaparin. A cost–utility model (health care perspective),
populated by the RECORD1-2 trials, assessed cost-effectiveness
of rivaroxaban versus both durations of enoxaparin over ﬁve
years. Risks of VTE and post-thrombotic syndrome beyond the
trial period were estimated from published data. Costs, in euros
(€), were derived from published Spanish sources. Utilities were
derived from published literature. Enoxaparin prophylaxis after
THR in Spain lasts approximately 27 days. Hence, in addition to
separate analyses based on RECORD1 and 2, RECORD1-2 data
were pooled to allow the cost-effectiveness of 35 days rivaroxa-
ban versus the Spanish enoxaparin duration to be estimated.
RESULTS: Thirty-ﬁve days rivaroxaban dominated 35 days
enoxaparin, with a small QALY gain and cost savings of €48.10
per patient. Rivaroxaban,was also cost-effective versus 12 days
enoxaparin (incremental cost per QALY, €3156). Rivaroxaban
remained dominant over enoxaparin when RECORD1-2 data
were combined (QALY gain, 0.011; cost savings per patient,
€12.24). Probabilistic sensitivity analyses showed rivaroxaban
dominating in 60% of cases and cost-effective in 100% (cost per
QALY; €20,000) CONCLUSIONS: Rivaroxaban is cost-
effective versus both 12 days and 35 days enoxaparin, for pre-
venting VTE following THR in Spain.
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OBJECTIVES: Assess cost-effectiveness of 35 days rivaroxaban,
an oral direct Factor Xa inhibitor, versus 12 days and 35 days
subcutaneous enoxaparin for prevention of venous throm-
boembolism (VTE) following total hip replacement (THR).
METHODS: Rivaroxaban regimens were compared with
enoxaparin regimens following THR in two large randomized
controlled trials. In RECORD1, patients received 35 days
prophylaxis with rivaroxaban or enoxaparin. In RECORD2,
patients received 35 days rivaroxaban or 12 days enoxaparin.
The duration of enoxaparin in RECORD1 represents the ACCP-
recommended duration of prophylaxis following THR, but in
Canada a shorter duration is often applied. In RECORD1, rivar-
oxaban reduced total VTE (composite: any DVT, non-fatal PE,
all-cause mortality) by 70% versus enoxaparin after 35 days
prophylaxis. The reduction in symptomatic VTE with rivaroxa-
ban was not statistically signiﬁcant and not included in the
model. In RECORD2, rivaroxaban reduced total VTE by 79%
and symptomatic VTE by 80% versus 12 days enoxaparin. A
cost–utility model (Ministry of Health perspective) assessed cost-
effectiveness of rivaroxaban versus both durations of enoxaparin
over ﬁve years. The model is populated by RECORD1-2 trials,
while published epidemiological and clinical data estimated the
risk of further VTE events and post-thrombotic syndrome
beyond the trial period. Costs were derived from published
Canadian sources and expressed in 2008 Canadian Dollars (C$).
Utilities were derived from published literature. Potential savings
from oral administration were also included. RESULTS: Thirty-
ﬁve days rivaroxaban dominated 35 days enoxaparin, with a
small QALY gain and savings of C$282.58 per patient. Cost
savings are driven mainly by reduced outpatient administration
costs. Probabilistic sensitivity analyses showed this dominance in
98% of cases. Rivaroxaban was also cost-effective versus 12 days
enoxaparin, with an incremental cost per QALY of C$33,323.
CONCLUSIONS: Rivaroxaban is cost-effective versus both 12
days and 35 days enoxaparin, for the prevention of VTE follow-
ing THA in Canada.
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OBJECTIVES: Assess cost-effectiveness of rivaroxaban, an oral
direct Factor Xa inhibitor, versus subcutaneous enoxaparin for
prevention of venous thromboembolism (VTE) following total
knee replacement (TKR) in the UK and Spain. METHODS:
RECORD3, a large randomized controlled trial, compared
VTE prophylaxis for 12 days with rivaroxaban versus 12 days
enoxaparin following TKR. Rivaroxaban reduced total VTE
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(composite: any DVT, non-fatal PE, all-cause mortality) by 49%
and symptomatic VTE by 66% versus enoxaparin. A cost–utility
model (health care perspective) assessed the cost-effectiveness
over ﬁve years following TKR of rivaroxaban versus enoxaparin
in the UK and Spain, two large European countries with different
approaches to post-surgical prophylaxis and patient manage-
ment. The model was populated using RECORD3 data. Pub-
lished epidemiological and clinical data estimated risks of VTE
and post-thrombotic syndrome beyond the trial period. Costs
were derived from published local sources and expressed in
pounds (£) for the UK and euros (€) for Spain. Utilities were
taken from a systematic literature review. Potential savings from
oral administration were included in the UK analysis only, as in
Spain, drug administration costs are included in hospitalisation
charges. RESULTS: The model showed rivaroxaban produced
improved health outcomes and cost savings versus enoxaparin in
the UK and Spain (dominance). Improved health outcomes were
similar across both countries, while rivaroxaban produced cost
savings of £89.15 per patient in the UK and €144.93 in Spain.
Savings were driven by reduced costs of treating symptomatic
VTE and associated long term complications, as well as oral
outpatient administration in the UK. In both countries, pro-
babilistic sensitivity analyses showed rivaroxaban maintained
dominance versus enoxaparin in more than 99% of cases.
CONCLUSIONS: Rivaroxaban is cost-effective following TKR
within the different health care systems of both these two major
European countries.
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OBJECTIVES: Assess cost-effectiveness of 35 days rivaroxaban,
an oral direct Factor Xa inhibitor, versus 12 days and 35 days
subcutaneous enoxaparin for prevention of venous throm-
boembolism (VTE) following total hip replacement (THR).
METHODS: Rivaroxaban regimens were compared with dif-
ferent enoxaparin regimens following THR in two large ran-
domized controlled trials. RECORD1 compared 35 days
prophylaxis with rivaroxaban or enoxaparin, while RECORD2
compared 35 days rivaroxaban with 12 days enoxaparin. While
the ACCP and NICE recommend up to 35 days prophylaxis in
higher-risk patients after THR, a shorter duration is often used
in the UK and elsewhere. In RECORD1, rivaroxaban reduced
total VTE (composite: any DVT, non-fatal PE, all-cause mor-
tality) by 70% versus enoxaparin after 35 days prophylaxis,
although the reduction in symptomatic VTE with rivaroxaban
was not statistically signiﬁcant. In RECORD2, rivaroxaban
reduced total VTE by 79% and symptomatic VTE by 80%
versus 12 days enoxaparin. A cost–utility model (health care
perspective) assessed cost-effectiveness of rivaroxaban versus
both durations of enoxaparin over the ﬁve years following
surgery. The model was populated by RECORD1-2 data while
published epidemiological and clinical data estimated risks of
VTE and post-thrombotic syndrome beyond the trial period.
Costs (2008 pounds [£]) were derived from published sources.
Utilities were taken from a systematic literature review. Poten-
tial savings associated with administration and monitoring were
also included. RESULTS: Thirty-ﬁve days rivaroxaban domi-
nated 35 days enoxaparin, yielding improved health outcomes
(QALYs) and savings of £67.82 per patient. Savings were
driven mainly by reduced outpatient administration costs.
Rivaroxaban also dominated 12 days enoxaparin, with a
QALY gain of 0.022 and savings of £22.38. Probabilistic
sensitivity analyses showed dominance in 98% of cases versus
35 days enoxaparin and 55% versus 12 days enoxaparin.
CONCLUSIONS: Rivaroxaban is cost-effective versus both
12 and 35 days enoxaparin, for prevention of VTE following
THR in the UK.
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OBJECTIVES: Assess economic impact of rivaroxaban, an oral
direct Factor Xa inhibitor, in VTE prevention following total hip
and total knee replacement (THR/TKR). METHODS: Rivaroxa-
ban regimens were compared with enoxaparin regimens for VTE
prevention in three large randomized controlled trials. For THR,
35 days rivaroxaban was compared with 35 days enoxaparin
(RECORD1), or 12 days enoxaparin (RECORD2). RECORD3
compared rivaroxaban and enoxaparin for 12 days following
TKR. Rivaroxaban reduced total VTE (composite: any DVT,
non-fatal PE, all-cause mortality) following THR by 70% versus
35 days enoxaparin and 79% versus 12 days enoxaparin. Fol-
lowing TKR, rivaroxaban reduced total VTE by 49% versus
enoxaparin. Bleeding was similar with both agents. An economic
model (health care perspective) assessed clinical and economic
consequences of rivaroxaban versus enoxaparin for ﬁve years
following surgery. The model was populated using RECORD
1–3 data and calculated outcomes for total VTE and symptom-
atic VTE. Cost results for the latter are presented here. Incidences
for VTE and post-thrombotic syndrome after the trials were
estimated from published data. Costs, (2008 euros [€]), were
derived from published Italian sources. As the Italian rivaroxa-
ban price is not published, rivaroxaban and enoxaparin costs
were excluded. RECORD 1–3 data were combined to estimate
costs and consequences of rivaroxaban versus enoxaparin for
THR/TKR. RESULTS: Overall improvement in outcomes with
rivaroxaban following THR and TKR was 0.021 symptomatic
VTE events per patient undergoing surgery; non-drug costs were
reduced by €81.32. These were consistent with individual THR
and TKR results when the RECORD trials were analysed sepa-
rately. In 2004, 96,000 THR and TKR were performed in Italy.
Rivaroxaban could yield total annual non-drug cost savings of
approximately €7.6 million. CONCLUSIONS: Rivaroxaban
thromboprophylaxis following THR or TKR may improve
health outcomes and reduce non-drug costs versus existing
approaches. Hence rivaroxaban may represent a more efﬁcient
approach to VTE prophylaxis in Italy.
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OBJECTIVES: Previous European research has shown that lap-
aroscopic surgery is frequently complicated by the need for adhe-
siolysis due to adhesions caused by previous surgery. In Europe
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